ClinicalTrials.gg
CompletedNCT03414931Updated Dec 1, 2020

NMDA Modulation in Major Depressive Disorder in Late- Life

A Phase 2 interventional study of NMDA and Sertraline in Depressive Disorder, Major, sponsored by Chang Gung Memorial Hospital. Completed at 2 sites in Taiwan. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2020-12-01.

Sponsored by Chang Gung Memorial Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years after the study started (first participant enrolled Jan 2016, registered Jan 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 69 studies in Depressive Disorder, Major with a site in Taiwan — 13 open to participants now, 13 under way, 6 of them phase 3. Depressive Disorder, Major · Taiwan.

Enrollment
32nd of 64
136 · median 128
Started
2016
with 3 others
Phase 2
8 of 69
2 open now
Registered
34th of 69
by date
Lead sponsor
4 of 69
Chang Gung Memorial Hospital

Among the 69 studies in Depressive Disorder, Major with a site in Taiwan, this one is the 32nd largest by enrollment of the 64 interventional ones that give a count, is one of 4 that started in 2016, is one of 8 in phase 2, and was the 34th registered.

Depressive Disorder, Major

3,050 studies on the registry are indexed under Depressive Disorder, Major; 594 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

13 of the 69 studies in Depressive Disorder, Major with a site in Taiwan are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 417 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 297 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Depressive Disorder, Major with a site in Taiwan, or all of them as a file.
02

Study summary

Major depressive disorder (MDD) is a complex and multi-factorial disorder. Most of the current antidepressants are based upon the monoamine hypothesis which cannot fully explain the etiology of depression. Many elderly patients have significant side effects after treatment with antidepressants which hamper the motivation for treatment and medication adherence. NMDA hypofunction has been implicated in the pathophysiology of depression. MDD in the elderly is often associated with cognitive deficits which are not necessarily recovered by current antidepressants. The NMDA receptor regulates synaptic plasticity, memory, and cognition. In our previous studies, cognitive improvement has been observed with treatment of NMDA enhancers. Therefore, this study will examine the efficacy and safety as well as cognitive function improvement of NMDAE in the treatment of MDD in the elderly by comparing with sertraline (a selective serotonin reuptake inhibitor [SSRI]) and placebo.

The investigator will enroll elderly patients with MDD for an 8-week treatment. All patients will be randomly assigned into three groups: NMDAE, sertraline, or placebo. The investigator will biweekly measure clinical performances. Cognitive functions will be assessed at baseline and at endpoint of treatment by a battery of tests. The investigator hypothesize that NMDAE can safely yield better efficacy than placebo and sertraline for elderly patients with MDD.

03

Conditions studied

  • Depressive Disorder, Major
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a (American Psychiatric Association 1994) diagnosis of MDD
  • 17-item Hamilton Rating Scale for Depression total score ≥ 18
  • Free of psychotropic drugs for at least 2 weeks
  • Have a (Folstein, Folstein et al. 1975) score ≥ 20

Exclusion criteria

Exclusion Criteria:

  • Current substance abuse or history of substance dependence in the past 6 months
  • Use of depot antipsychotics in the past 6 months
  • History of epilepsy, head trauma, stroke or other serious medical or neurological illness
  • Bipolar depression, schizophrenia or other psychotic disorder
  • Moderate-severe suicidal risks
  • Severe cognitive impairment
  • Initiating or stopping formal psychotherapy within six weeks prior to enrollment
  • A history of poor response to SSRIs or other antidepressants
  • A history of previously received electroconvulsive therapy
  • A history of severe adverse reaction to SSRIs or other antidepressants
  • Inability to follow protocol
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    NMDAE

    An NMDA enhancer

    Drug: NMDA

  • Active comparator
    SSRI

    Sertraline

    Drug: Sertraline

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo - Cap

Interventions

  • DrugNMDA

    Use of an NMDA enhancer for the treatment of MDD in late life

    Also known as: NMDAE

  • Use of SSRI as an active comparator

  • DrugPlacebo - Cap

    Use of placebo as a comparator

06

What researchers measure

Primary outcomes

  1. Change from baseline of 17-item Hamilton Rating Scale for Depression

    Assessment of depressive symptoms. The 17-item Hamilton Rating Scale for Depression will be measured biweekly.

    Time frame: Week 0, 2, 4, 6, 8

  2. Change from baseline of Perceived Stress Scale

    Assessment of stress and anxiety symptoms. The Perceived Stress Scale will be measured biweekly

    Time frame: Week 0, 2, 4, 6, 8

Secondary outcomes

  1. Drop out rate

    The rate of drop out

    Time frame: Week 0, 2, 4, 6, 8

  2. Change from baseline of Geriatric Depression Scale

    Assessment of geriatric depressive symptoms. The Geriatric Depression Scale will be measured biweekly

    Time frame: Week 0, 2, 4, 6, 8

  3. Clinical Global Impression

    Assessment of global improvement

    Time frame: Week 2, 4, 6, 8

  4. Cognitive function

    A battery of tests to assess the cognitive function including speed of processing (category fluency) and verbal and nonverbal working memory

    Time frame: Week 0, 8

  5. Change from baseline of Beck's Suicide Scale

    Assessment of suicidal symptoms. The Beck's Suicide Scale will be measured biweekly

    Time frame: Week 0, 2, 4, 6, 8

07

Study locations

2 sites
  • Chang Gung Memorial Hospital
    Kaohsiung, 886, Taiwan
  • China Medical University Hospital
    Taichung, 404, Taiwan
08

References and documents

Publications

  • Lin CH, Wang SH, Lane HY. Effects of Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, on Perceived Stress and Cognitive Function Among Patients With Late-Life Depression: A Randomized, Double-Blind, Sertraline- and Placebo-Controlled Trial. Int J Neuropsychopharmacol. 2022 Aug 4;25(7):545-555. doi: 10.1093/ijnp/pyac006. PubMed 35023557 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Nov 2020, 58 months.

Of 99 non-industry phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 57. This study's 58 months is above that.

Counting every sponsor, half of 197 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2018
First posted
Jan 30, 2018
StartActual
Jan 2016
Primary completionActual
Nov 2020
CompletionActual
Nov 2020
Last update
Dec 1, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03414931
Responsible party
Sponsor
First posted
Jan 30, 2018
Start date
Jan 2016
Primary completion
Nov 2020
Completion
Nov 2020
Last update
Dec 1, 2020

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion